Develop potent, targeted and robust bispecific products
Focused completely on the development of bispecific antibodies, the World Bispecific Summit represents a unique opportunity to engage with your peers to discuss strategies to overcome the key challenges holding back progress in the field.
Incorporating insights from AbbVie, Genentech, Pfizer, Merck and MacroGenics, this meeting will include more developmental and clinical insights than ever before. Rather than presenting vague overviews of platforms, this meeting will delve directly into the technical and scientific insights, enabling you to advance your candidate therapeutic into the clinic as efficiently and cost-effectively as possible.
Join the Bispecifics community in Boston and overcome the most pressing industry challenges, allowing you to:
- Integrate lessons learned from the clinic into your own work by understanding the key factors involved in the successful clinical progression of candidate bispecifics with insights from Abbvie’s
- Optimize synergistic target selection by understanding how probability of selection success can be improved through the strategic design of libraries, with Jonathan Davis, Bristol-Myers Squibb
- Understand the true value and utility of formats with head-to-head comparisons of key format characteristics, enabling you to enhance your future format design with experts from Eli Lilly, Roche, Jounce and Zymeworks
- Combine checkpoint pathways effectively by investigating the rationale and mechanistic understanding behind checkpoint-targeting bispecifics, with insights from Paul Moore, Macrogenics
“Very well organised conference and very focused on topics that matter. Top speakers.
The best conference in the field in my opinion.”
“This meeting provided a very good, detailed and critical overview of the field of bispecific biologics.”